Circulation, Hypertension and Preserved Ejection Fraction

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Circulation

OCTOBER 13, 2023

Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023. BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. per 100 patient-years) compared with nonresistant hypertension (2.7

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction

Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell–Derived Cardiac Organoids

Circulation: Heart Failure

JANUARY 28, 2025

Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. compared with single condition exposure 5.21.3% (obesity), 6.73.5% (hypertension), and 9.01.1% (diabetes;P<0.001).

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Obesity Diabetes

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study

Circulation

MARCH 16, 2025

Circulation, Volume 151, Issue 11 , Page e763-e763, March 18, 2025.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension

Letter by Dai et al Regarding Article, “Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction”

Circulation

MARCH 9, 2025

Circulation, Volume 151, Issue 10 , Page e686-e686, March 11, 2025.

Preserved Ejection Fraction

Preserved Ejection Fraction Article Heart Failure Pulmonary

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146852-A4146852, November 12, 2024. Introduction:The demographics of patients with pulmonary arterial hypertension (PAH) is shifting towards older age, increased comorbidity burden, and an increase in the risk of left ventricular (LV) diastolic dysfunction. 2022 were included.

Pulmonary

Pulmonary Hypertension Preserved Ejection Fraction Outcomes

Abstract 4139791: A short version of HFD/L-NAME mouse model enabling time-effective proof of concept studies to evaluate drugs targeting the cardiometabolic and mild hypertension associated HFpEF phenotype.

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139791-A4139791, November 12, 2024. Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups.

Preserved Ejection Fraction

Preserved Ejection Fraction Hypertension Blood Pressure Obesity

Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF

Circulation

APRIL 1, 2025

Circulation, Ahead of Print. BACKGROUND:Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells.

Preserved Ejection Fraction

Preserved Ejection Fraction Obesity Heart Failure Hypertension

Trying to answer two casual queries on RV dysfunction

Dr. S. Venkatesan MD

AUGUST 3, 2024

However, It is surprising even in chronic pulmonary hypertension , the degree of RVH is not constant and homogenous.This is because , different parts of RV chamber has different wall thickness.Further, the pressure distribution from PA to RV is uneven. This may be correct when there is acute raise in RV after load, as in PE.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Pulmonary Heart Dysfunction

Abstract 4123391: CardioMEMS and Mavacamten: A Synergistic Approach in Managing Hypertrophic Obstructive Cardiomyopathy with HFpEF Phenotype

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4123391-A4123391, November 12, 2024. The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction

Preserved Ejection Fraction Cardiomyopathy Heart Failure Pulmonary

Abstract 4134456: Hybrid Cardiac Targeting Peptide Ameliorates HFpEF Phenotype in Mice

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4134456-A4134456, November 12, 2024. Introduction:Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure which is rapidly rising in incidence in the US today. g/L of an iNOS inhibitor (N-Nitro-L-arginine methylester) to induce hypertension.

Preserved Ejection Fraction

Preserved Ejection Fraction Echocardiogram Exercise Diet

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Circulation Research 118.11 (2016): 1752-1770. References Ortega, Francisco B., Lavie, and Steven N. 2017): 451-463.

Obesity

Obesity BMI Heart Failure Cardiovascular Disease

Peroxiredoxin‐4, a marker of systemic oxidative stress, is associated with incident heart failure

European Journal of Heart Failure

APRIL 6, 2025

The aim of this study was to examine whether circulating peroxiredoxin-4 (Prx4), a marker of systemic oxidative stress, associates with incident HF and its subtypes. During a median follow-up of 12.6years, 349 (4.3%) HF events occurred of which 118 (33.8%) had HF with preserved ejection fraction.

Heart Failure

Heart Failure Preserved Ejection Fraction Cholesterol Obesity

Cardiovascular Update

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell–Derived Cardiac Organoids

Webinars

Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study

Letter by Dai et al Regarding Article, “Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction”

Abstract 4146852: Impact of Left Ventricular Diastolic Function in Pulmonary Arterial Hypertension Outcomes

Abstract 4139791: A short version of HFD/L-NAME mouse model enabling time-effective proof of concept studies to evaluate drugs targeting the cardiometabolic and mild hypertension associated HFpEF phenotype.

Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF

Trying to answer two casual queries on RV dysfunction

Abstract 4123391: CardioMEMS and Mavacamten: A Synergistic Approach in Managing Hypertrophic Obstructive Cardiomyopathy with HFpEF Phenotype

Abstract 4134456: Hybrid Cardiac Targeting Peptide Ameliorates HFpEF Phenotype in Mice

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Peroxiredoxin‐4, a marker of systemic oxidative stress, is associated with incident heart failure

Stay Connected